6978 Immunotech Biopharm Ltd HKEX · China

Immunotech Biopharm (6978) news

Immunotech Biopharm Ltd is a public biotech or pharmaceutical company listed on HKEX under the ticker 6978, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Immunotech Biopharm news

We have not published a story on Immunotech Biopharm yet. When there is news, it will appear here.

Questions about Immunotech Biopharm

What is the ticker symbol of Immunotech Biopharm?

Immunotech Biopharm Ltd trades under the ticker 6978 on HKEX.

Where is Immunotech Biopharm listed?

Immunotech Biopharm Ltd is listed on HKEX.

Which country or territory is Immunotech Biopharm listed under?

Our directory records Immunotech Biopharm Ltd under China.

What does Immunotech Biopharm do?

Our directory classifies Immunotech Biopharm Ltd as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Immunotech Biopharm?

The ISIN recorded for Immunotech Biopharm Ltd is KYG4721A1004.

Does aibio.space cover Immunotech Biopharm?

aibio.space lists Immunotech Biopharm Ltd among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Immunotech Biopharm?

Companies in our directory listed in the same country and business area as Immunotech Biopharm: Transcenta Holding, Zhong Zhu Healthcare Holding Co., HUBEI JUMPCAN PHARMACEUTICAL CO., LTD, Hightide Therapeutics, Yifan Pharmaceutical Co., Akeso.

Investor discussion: Immunotech Biopharm

Members talk about Immunotech Biopharm (6978). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Immunotech Biopharm, newest first. Each line links the filing it comes from.

Apr 29, 2026Listings
Trading status: EXCHANGE NOTICE - RESUMPTION OF TRADING. Source
Apr 28, 2026Listings
Trading status: (1) INSIDE INFORMATION UPDATE ON CONDITIONAL NEW DRUG APPLICATION FOR EAL FOR THE PREVENTION OF POSTOPERATIVE RECURRENCE OF LIVER CANCER (2) RESUMPTION OF TRADING. Source
Apr 28, 2026Listings
Trading status: TRADING HALT. Source
Apr 28, 2026Listings
Trading status: EXCHANGE NOTICE - TRADING HALT. Source
Feb 25, 2026Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION SUBSCRIPTION OF STRUCTURED DEPOSIT PRODUCT. Source
Feb 13, 2026Financings
Share or debt issue: COMPLETION OF ISSUE OF NEW CONVERTIBLE BONDS UNDER GENERAL MANDATE AND THE NOTE AND SETTLEMENT OF THE 2023 CONVERTIBLE BONDS. Source
Feb 9, 2026Financings
Share or debt issue: PROPOSED ISSUE OF NEW CONVERTIBLE BONDS UNDER GENERAL MANDATE AND THE NOTE AND SETTLEMENT OF THE 2023 CONVERTIBLE BONDS. Source
Jan 20, 2026Financings
Share or debt issue: FRAMEWORK AGREEMENT IN RELATION TO THE ISSUE OF CONVERTIBLE BONDS UNDER GENERAL MANDATE AND THE NOTE. Source
Dec 8, 2025Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION SUBSCRIPTION OF STRUCTURED DEPOSIT PRODUCTS. Source
Nov 12, 2025Financings
Share or debt issue: RESULTS OF RIGHTS ISSUE ON THE BASIS OF ONE (1) RIGHTS SHARE FOR EVERY FIVE (5) EXISTING SHARES HELD ON THE RECORD DATE AND ADJUSTMENTS TO THE CONVERSION PRICES OF THE CONVERTIBLE BONDS AND THE EXERCISE PRICE OF THE SHARE OPTIONS UNDER THE PRE-IPO SHARE OPTION SCHEME. Source
Oct 13, 2025Financings
Share or debt issue: EXCESS APPLICATION FORM. Source
Oct 13, 2025Financings
Share or debt issue: PROVISIONAL ALLOTMENT LETTER. Source
Oct 13, 2025Financings
Share or debt issue: RIGHTS ISSUE ON THE BASIS OF ONE (1) RIGHTS SHARE FOR EVERY FIVE (5) EXISTING SHARES HELD ON THE RECORD DATE. Source
Sep 22, 2025Listings
Trading status: EXCHANGE NOTICE - RESUMPTION OF TRADING. Source
Sep 19, 2025Listings
Trading status: (1) PROPOSED RIGHTS ISSUE ON THE BASIS OF ONE (1) RIGHTS SHARE FOR EVERY FIVE (5) EXISTING SHARES HELD ON THE RECORD DATE (2) RESUMPTION OF TRADING. Source
Sep 19, 2025Listings
Trading status: TRADING HALT. Source
Sep 19, 2025Listings
Trading status: EXCHANGE NOTICE - TRADING HALT. Source

Press releases

Headlines of Immunotech Biopharm's own announcements, newest first. Each opens the full release on the newswire that carried it.

Sep 30, 2026HKEXnews
SUPPLEMENTAL ANNOUNCEMENT TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025
Aug 21, 2026HKEXnews
ANNOUNCEMENT OF THE INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026
Jun 3, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT UPDATE ON STATUS OF EAL AND APPROVAL FOR CLINICAL TRANSLATIONAL APPLICATION OF ATL
Apr 30, 2026HKEXnews
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 30 APRIL 2026
Apr 29, 2026HKEXnews
EXCHANGE NOTICE - RESUMPTION OF TRADING
Apr 28, 2026HKEXnews
(1) INSIDE INFORMATION UPDATE ON CONDITIONAL NEW DRUG APPLICATION FOR EAL FOR THE PREVENTION OF POSTOPERATIVE RECURRENCE OF LIVER CANCER (2) RESUMPTION OF TRADING
Apr 28, 2026HKEXnews
TRADING HALT
Apr 28, 2026HKEXnews
EXCHANGE NOTICE - TRADING HALT
Apr 7, 2026HKEXnews
CHANGE OF DATE OF ANNUAL GENERAL MEETING AND BOOK CLOSURE PERIOD
Apr 7, 2026HKEXnews
NOTICE OF ANNUAL GENERAL MEETING
Mar 20, 2026HKEXnews
TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE
Mar 20, 2026HKEXnews
TERMS OF REFERENCE OF THE AUDIT COMMITTEE
Mar 20, 2026HKEXnews
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2025
Feb 25, 2026HKEXnews
DISCLOSEABLE TRANSACTION SUBSCRIPTION OF STRUCTURED DEPOSIT PRODUCT
Feb 13, 2026HKEXnews
COMPLETION OF ISSUE OF NEW CONVERTIBLE BONDS UNDER GENERAL MANDATE AND THE NOTE AND SETTLEMENT OF THE 2023 CONVERTIBLE BONDS
Feb 9, 2026HKEXnews
PROPOSED ISSUE OF NEW CONVERTIBLE BONDS UNDER GENERAL MANDATE AND THE NOTE AND SETTLEMENT OF THE 2023 CONVERTIBLE BONDS
Jan 27, 2026HKEXnews
CONTINUING CONNECTED TRANSACTION IN RELATION TO PROVISION OF CELL THERAPY PROCESSING SERVICES TO TASLY
Jan 20, 2026HKEXnews
FRAMEWORK AGREEMENT IN RELATION TO THE ISSUE OF CONVERTIBLE BONDS UNDER GENERAL MANDATE AND THE NOTE
Dec 8, 2025HKEXnews
DISCLOSEABLE TRANSACTION SUBSCRIPTION OF STRUCTURED DEPOSIT PRODUCTS
Nov 12, 2025HKEXnews
RESULTS OF RIGHTS ISSUE ON THE BASIS OF ONE (1) RIGHTS SHARE FOR EVERY FIVE (5) EXISTING SHARES HELD ON THE RECORD DATE AND ADJUSTMENTS TO THE CONVERSION PRICES OF THE CONVERTIBLE BONDS AND THE EXERCISE PRICE OF THE SHARE OPTIONS UNDER THE PRE-IPO SHARE OPTION SCHEME

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:6978 on TradingView.

Listing details

Company: Immunotech Biopharm Ltd
Ticker: 6978
Listing: HKEX
Country or territory: China
Business scope: Pharmaceuticals: Major
ISIN: KYG4721A1004
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction